TAIHUSNOW CO.,LTD.
838262
Guangdong Brandmax Marketing
300805
Guangdong Transtek Medical Electronics
300562
Suzhou Kingswood Education Technology
300192
Broadex Technologies
300548
CN Stock MarketDetailed Quotes
600867 Tonghua Dongbao Pharmaceutical
- 8.39
- -0.03-0.36%
Trading Dec 16 10:49 CST
16.63BMarket Cap48.78P/E (TTM)
8.47High8.38Low47.60KlotVolume8.42Open8.42Pre Close40.08MTurnover0.24%Turnover Ratio14.24P/E (Static)1.98BShares10.8452wk High2.59P/B16.63BFloat Cap7.0252wk Low9.26Limit Up1.98BShs Float25.86Historical High7.58Limit Down1.07%Amplitude-2.04Historical Low0.25Dividend TTM8.42Avg Price25.65KlotAsk2.98%Div YieldTTM100Lot Size21.17KlotBid
Tonghua Dongbao Pharmaceutical Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -30.78%1.45B | -45.84%740.01M | -11.12%591.39M | 10.69%3.08B | -0.36%2.09B | -1.53%1.37B | -25.03%665.36M | -14.98%2.78B | -14.50%2.1B | -16.53%1.39B |
| Operating revenue | -30.78%1.45B | -45.84%740.01M | -11.12%591.39M | 10.69%3.08B | -0.36%2.09B | -1.53%1.37B | -25.03%665.36M | -14.98%2.78B | -14.50%2.1B | -16.53%1.39B |
| Other operating revenue | ---- | -5.94%15.65M | ---- | 299.83%145.81M | ---- | 7.32%16.63M | ---- | -25.90%36.47M | ---- | 9.95%15.5M |
| Total operating cost | 8.32%1.37B | -5.62%785.45M | -4.67%376.19M | -5.64%1.77B | -8.82%1.26B | -9.45%832.24M | -10.14%394.62M | -6.05%1.88B | -3.74%1.39B | 0.35%919.07M |
| Operating cost | -16.64%369.64M | -34.76%200.19M | -15.42%126.07M | -0.77%612.77M | -1.64%443.41M | -0.01%306.83M | -0.94%149.05M | 7.27%617.51M | 2.47%450.79M | 1.97%306.87M |
| Operating tax surcharges | -11.76%9.17M | -13.66%5.46M | -4.96%3.65M | -3.64%14.04M | -15.54%10.39M | -25.30%6.32M | -12.36%3.84M | 29.33%14.57M | 3.94%12.3M | 12.55%8.46M |
| Operating expense | 24.42%788.4M | 12.49%449.11M | 4.12%182.84M | -2.22%912.83M | -7.71%633.67M | -12.48%399.25M | -16.09%175.61M | -8.70%933.51M | -3.05%686.61M | 7.47%456.16M |
| Administration expense | 4.44%123.58M | 2.20%83.43M | -10.10%37.35M | -25.57%134.47M | -11.26%118.33M | -13.69%81.63M | -13.88%41.55M | -22.28%180.65M | -20.39%133.35M | -16.22%94.58M |
| Financial expense | 135.80%2.86M | 101.98%129.79K | 77.10%-746.28K | 58.56%-5.58M | 15.44%-7.98M | -0.08%-6.57M | -26.23%-3.26M | -66.33%-13.45M | -55.86%-9.44M | -48.45%-6.56M |
| -Interest expense (Financial expense) | 1,792.10%9.27M | 2,515.52%5.33M | 1,739.97%2.4M | 809.72%4.54M | 286.08%489.85K | 12.07%-220.65K | -1.27%-146.3K | 0.00%-639K | 45.07%-263.25K | 21.46%-250.94K |
| -Interest Income (Financial expense) | 21.86%-6.77M | 9.85%-5.79M | -20.02%-3.76M | 12.22%-11.68M | 7.39%-8.66M | 0.39%-6.42M | -28.21%-3.13M | -79.00%-13.3M | -62.72%-9.35M | -53.12%-6.44M |
| Research and development | 14.06%75.09M | 5.28%47.14M | -2.92%27.02M | -28.46%104.96M | -41.37%65.83M | -24.84%44.78M | -5.11%27.83M | -12.07%146.71M | -5.07%112.28M | -20.08%59.57M |
| Credit Impairment Loss | 212.58%13.06M | 327.32%13.06M | ---- | -400.83%-20.25M | -195.11%-11.6M | -147.10%-5.75M | --3.72M | 495.26%6.73M | --12.2M | --12.2M |
| Asset Impairment Loss | -4,668.55%-64.85M | -4,646.75%-64.56M | ---- | -23.66%-15.28M | ---1.36M | ---1.36M | ---- | 45.95%-12.36M | ---- | ---- |
| Other net revenue | 13.17%57.91M | -95.47%1.29M | 25.40%23.66M | -93.21%63.16M | -94.50%51.17M | -96.90%28.42M | -96.45%18.87M | 229.78%929.93M | 280.51%930.04M | 1,744.56%915.35M |
| Fair value change income | ---- | 93.00%-67.27K | 93.00%-67.27K | -46.29%516.49K | ---961.61K | ---961.61K | ---961.61K | 360.64%961.61K | ---- | ---- |
| Invest income | 45.78%88.86M | 47.70%48.21M | 43.59%20.24M | -90.11%91.93M | -93.31%60.96M | -96.36%32.64M | -97.34%14.1M | 213.04%929.36M | 307.21%911.63M | 2,575.27%897.44M |
| -Including: Investment income associates | 45.11%86.53M | 51.35%47.73M | 54.74%20.23M | 95.32%89.17M | 94.17%59.63M | 53.98%31.54M | 12.11%13.07M | -6.01%45.65M | -16.42%30.71M | -9.06%20.48M |
| Asset deal income | --15.53M | --107.49K | --107.49K | -98.17%3.46K | ---- | ---- | ---- | 108.10%189.19K | -98.58%189.61K | -98.17%194.77K |
| Other revenue | 28.42%5.31M | 17.86%4.53M | 67.84%3.38M | 23.29%6.23M | -31.34%4.14M | -30.24%3.85M | 84.21%2.01M | -59.14%5.05M | 173.74%6.03M | 427.42%5.51M |
| Operating profit | -84.43%136.89M | -107.85%-44.15M | -17.52%238.86M | -25.36%1.37B | -46.51%879.01M | -59.35%562.5M | -70.46%289.61M | 18.05%1.83B | 30.44%1.64B | 73.84%1.38B |
| Add:Non operating Income | 102.33%3.99M | -56.22%862.28K | -94.53%106.48K | 202.40%5.57M | 1,234.08%1.97M | 1,621.67%1.97M | 2,548.55%1.95M | 317.17%1.84M | -26.66%147.96K | 146.04%114.4K |
| Less:Non operating expense | 10,372.24%256.05M | 114,520.82%255.04M | 8.00%227.62K | 291.70%4.76M | 256.86%2.45M | -64.76%222.51K | -66.60%210.76K | -92.04%1.21M | -86.60%685.15K | -75.84%631.34K |
| Total profit | -113.11%-115.16M | -152.87%-298.33M | -18.06%238.74M | -25.34%1.37B | -46.52%878.54M | -59.21%564.25M | -70.27%291.34M | 19.23%1.83B | 30.91%1.64B | 74.33%1.38B |
| Less:Income tax cost | -141.26%-48.73M | -185.65%-67.8M | -40.79%24.08M | -20.07%197.97M | -50.79%118.11M | -60.57%79.16M | -72.64%40.67M | 9.67%247.69M | 28.25%240.01M | 67.76%200.76M |
| Net profit | -108.74%-66.43M | -147.52%-230.53M | -14.37%214.66M | -26.17%1.17B | -45.79%760.43M | -58.98%485.09M | -69.84%250.67M | 20.88%1.58B | 31.37%1.4B | 75.50%1.18B |
| Net profit from continuing operation | -108.77%-66.18M | -148.05%-230.15M | -12.63%214.59M | -26.29%1.17B | -46.27%754.5M | -59.51%478.95M | -70.47%245.61M | 20.95%1.58B | 32.11%1.4B | 76.20%1.18B |
| Net income from discontinuing operating | -104.35%-258.01K | -106.24%-383.09K | -98.62%69.92K | 287.33%1.38M | 455.17%5.93M | 1,347.66%6.13M | 1,228.41%5.07M | -524.06%-739.23K | -135.60%-1.67M | -120.62%-491.7K |
| Less:Minority Profit | -122.28%-61.55K | -113.18%-37.95K | -106.84%-16.23K | 243.76%87.15K | 347.91%276.19K | 817.40%287.87K | 917.99%237.21K | -117.75%-60.63K | -207.34%-111.41K | 8.76%-40.13K |
| Net profit of parent company owners | -108.73%-66.37M | -147.54%-230.49M | -14.28%214.68M | -26.17%1.17B | -45.81%760.15M | -59.00%484.8M | -69.87%250.44M | 20.92%1.58B | 31.39%1.4B | 75.49%1.18B |
| Earning per share | ||||||||||
| Basic earning per share | -107.89%-0.03 | -150.00%-0.12 | -15.38%0.11 | -25.32%0.59 | -45.71%0.38 | -59.32%0.24 | -68.29%0.13 | 23.44%0.79 | 34.62%0.7 | 78.79%0.59 |
| Diluted earning per share | -107.89%-0.03 | -150.00%-0.12 | -15.38%0.11 | -25.32%0.59 | -45.71%0.38 | -59.32%0.24 | -68.29%0.13 | 23.44%0.79 | 34.62%0.7 | 78.79%0.59 |
| Other composite income | -99.49%-1.1M | -1.85%-553.17K | ||||||||
| Other composite income of parent company owners | ---- | ---- | ---- | -99.49%-1.1M | ---- | ---- | ---- | -1.85%-553.17K | ---- | ---- |
| Total composite income | -108.74%-66.43M | -147.52%-230.53M | -14.37%214.66M | -26.21%1.17B | -45.79%760.43M | -58.98%485.09M | -69.84%250.67M | 20.89%1.58B | 31.37%1.4B | 75.50%1.18B |
| Total composite income of parent company owners | -108.73%-66.37M | -147.54%-230.49M | -14.28%214.68M | -26.22%1.17B | -45.81%760.15M | -59.00%484.8M | -69.87%250.44M | 20.92%1.58B | 31.39%1.4B | 75.49%1.18B |
| Total composite income of minority owners | -122.28%-61.55K | -113.18%-37.95K | -106.84%-16.23K | 243.76%87.15K | 347.91%276.19K | 817.40%287.87K | 917.99%237.21K | -117.75%-60.63K | -207.34%-111.41K | 8.76%-40.13K |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Zhongzhun Certified Public Accountants (Special General Partnership) | -- | -- | -- | Zhongzhun Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
